In three practice guidelines from ASCO, experts provide evidence-based recommendations that address overarching clinical questions for the management of patients with pancreatic cancer. These guidelines offer improved strategies for interdisciplinary patient management and highlight the need for further research in several areas.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Khorana, A. A. et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 34, 2541–2556 (2016).
Balaban, E. P. et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 34, 2654–2668 (2016).
Sohal, D. P. et al. Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2016.67.1412 (2016).
Bockhorn, M. et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 155, 977–988 (2014).
Chandrasegaram, M. D. et al. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Br. J. Surg. 102, 1459–1472 (2015).
Strobel, O. et al. Pancreatic cancer surgery: the new R-status counts. Ann. Surg. http://dx.doi.org/10.1097/SLA.0000000000001731 (2016).
Neoptolemos, J. P. et al. Adjuvant chemotherapy with fluorouracil plus folinic acid versus gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304, 1073–1081 (2010).
Neoptolemos, J. P. et al. ESPAC-4: a multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J. Clin. Oncol. Abstr. 34, aLBA4006 (2016).
Strobel, O. et al. Pancreatic adenocarcinoma: number of positive nodes allows to distinguish several N categories. Ann. Surg. 261, 961–969 (2015).
Allen, P. J. et al. Multi-institutional Validation Study of the American Joint Commission on Cancer (8th edition) changes for T and N staging in patients with pancreatic adenocarcinoma. Ann. Surg. http://dx.doi.org/10.1097/SLA.0000000000001763 (2016).
Suker, M. et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 17, 801–810 (2016).
Hackert, T. et al. Locally advanced pancreatic cancer: neoadjuvant therapy with FOLFIRINOX results in resectability in 60% of the patients. Ann. Surg. http://dx.doi.org/10.1097/SLA.0000000000001850 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Strobel, O., Büchler, M. Clinical practice guidelines — what is the evidence?. Nat Rev Clin Oncol 13, 593–594 (2016). https://doi.org/10.1038/nrclinonc.2016.127
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2016.127
This article is cited by
-
Optimizing the outcomes of pancreatic cancer surgery
Nature Reviews Clinical Oncology (2019)
